The deceptive simplicity of a single hydrogen atom moving across a molecular scaffold has long been the invisible wall separating promising drug candidates from clinical failure. This phenomenon, known as tautomerism, involves the rapid relocation of a proton and a corresponding shift in double
Technology suppliers are currently focused on removing technical burdens to allow smaller biotech firms to access high-level efficiency and reproducibility. The biomanufacturing industry stands at a critical juncture where the simple accumulation of biological data no longer provides a competitive
By leveraging a system of base and fibre posets, computational chemists can now characterize the search space for new drugs with mathematical precision and formal semantics. The pharmaceutical industry is currently witnessing a significant shift as artificial intelligence moves from being an
Reliability and standardization are the new metrics of success as the industry attempts to ensure that biological data is reproducible across different batches and global locations. This shift follows a decade of intense focus on the computational "dry lab" side of drug discovery, where artificial
Autonomous laboratories are reducing the cost of innovation by allowing researchers to explore broad scientific domains with a minimal number of physical experiments. This shift represents a fundamental transformation in how LG AI Research approaches machine intelligence, moving away from broad,
Automated monitoring systems can track organoid morphology in real-time, providing critical data points that are nearly impossible to capture through manual inspection. This technological leap, driven by the collaboration between Molecular Devices and STEMCELL Technologies, addresses the historical
